{"pmid":32362922,"pmcid":"PMC7189258","title":"Myocardial injury is associated with higher mortality in patients with coronavirus disease 2019: a meta-analysis.","text":["Myocardial injury is associated with higher mortality in patients with coronavirus disease 2019: a meta-analysis.","J Geriatr Cardiol","Shao, Meng-Jiao","Shang, Lu-Xiang","Luo, Jun-Yi","Shi, Jia","Zhao, Yang","Li, Xiao-Mei","Yang, Yi-Ning","32362922"],"journal":"J Geriatr Cardiol","authors":["Shao, Meng-Jiao","Shang, Lu-Xiang","Luo, Jun-Yi","Shi, Jia","Zhao, Yang","Li, Xiao-Mei","Yang, Yi-Ning"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32362922","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.11909/j.issn.1671-5411.2020.04.009","keywords":["coronavirus disease 2019","meta-analysis","mortality","myocardial injury"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138496102825984,"score":9.490897,"similar":[{"pmid":32484975,"title":"Myocardial injury characterized by elevated cardiac troponin and in-hospital mortality of COVID-19: an insight from a meta-analysis.","text":["Myocardial injury characterized by elevated cardiac troponin and in-hospital mortality of COVID-19: an insight from a meta-analysis.","Elevation of high-sensitivity cardiac troponin (hs-cTn) is a surrogate of myocardial injury, which appears to be a common complication of coronavirus disease 2019 (COVID-19). In this study, a meta-analysis was performed to clarify the association between myocardial injury assessed by hs-cTn levels and in-hospital mortality in patients with COVID-19. All existing studies on myocardial injury in patients with COVID-19 were retrieved from PubMed and EMBASE through April 13, 2020. In cases where overlap of the study population or enrollment period was found in articles published from the same hospitals, the article with the largest number of patients was only included in the analysis. The pooled odds ratio was calculated using inverse variance weighted random-effects models. Six observational studies which included a total of 1,231 patients met the search criteria. The percentage of patients with hs-cTn levels varied across the studies (13-41%). Elevated hs-cTn levels were significantly associated with an increase in in-hospital mortality (pooled odds ratio, 22.7; 95% confidence interval, 13.6-38.1; P<0.001) with a moderate heterogeneity (I(2) =28%), suggesting that elevated hs-cTn levels might be used as a reliable marker of disease severity early in the course of COVID-19. This article is protected by copyright. All rights reserved.","J Med Virol","Aikawa, Tadao","Takagi, Hisato","Ishikawa, Kiyotake","Kuno, Toshiki","32484975"],"abstract":["Elevation of high-sensitivity cardiac troponin (hs-cTn) is a surrogate of myocardial injury, which appears to be a common complication of coronavirus disease 2019 (COVID-19). In this study, a meta-analysis was performed to clarify the association between myocardial injury assessed by hs-cTn levels and in-hospital mortality in patients with COVID-19. All existing studies on myocardial injury in patients with COVID-19 were retrieved from PubMed and EMBASE through April 13, 2020. In cases where overlap of the study population or enrollment period was found in articles published from the same hospitals, the article with the largest number of patients was only included in the analysis. The pooled odds ratio was calculated using inverse variance weighted random-effects models. Six observational studies which included a total of 1,231 patients met the search criteria. The percentage of patients with hs-cTn levels varied across the studies (13-41%). Elevated hs-cTn levels were significantly associated with an increase in in-hospital mortality (pooled odds ratio, 22.7; 95% confidence interval, 13.6-38.1; P<0.001) with a moderate heterogeneity (I(2) =28%), suggesting that elevated hs-cTn levels might be used as a reliable marker of disease severity early in the course of COVID-19. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Aikawa, Tadao","Takagi, Hisato","Ishikawa, Kiyotake","Kuno, Toshiki"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32484975","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/jmv.26108","keywords":["covid-19","coronavirus disease 2019","high-sensitivity cardiac troponin","in-hospital mortality","meta-analysis","myocardial injury"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668532114837995521,"score":121.239975},{"pmid":32391877,"title":"Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019.","text":["Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019.","AIMS: To investigate the characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019 (COVID-19). METHODS AND RESULTS: We enrolled 671 eligible hospitalized patients with severe COVID-19 from 1 January to 23 February 2020, with a median age of 63 years. Clinical, laboratory, and treatment data were collected and compared between patients who died and survivors. Risk factors of death and myocardial injury were analysed using multivariable regression models. A total of 62 patients (9.2%) died, who more often had myocardial injury (75.8% vs. 9.7%; P < 0.001) than survivors. The area under the receiver operating characteristic curve of initial cardiac troponin I (cTnI) for predicting in-hospital mortality was 0.92 [95% confidence interval (CI), 0.87-0.96; sensitivity, 0.86; specificity, 0.86; P < 0.001]. The single cut-off point and high level of cTnI predicted risk of in-hospital death, hazard ratio (HR) was 4.56 (95% CI, 1.28-16.28; P = 0.019) and 1.25 (95% CI, 1.07-1.46; P = 0.004), respectively. In multivariable logistic regression, senior age, comorbidities (e.g. hypertension, coronary heart disease, chronic renal failure, and chronic obstructive pulmonary disease), and high level of C-reactive protein were predictors of myocardial injury. CONCLUSION: The risk of in-hospital death among patients with severe COVID-19 can be predicted by markers of myocardial injury, and was significantly associated with senior age, inflammatory response, and cardiovascular comorbidities.","Eur Heart J","Shi, Shaobo","Qin, Mu","Cai, Yuli","Liu, Tao","Shen, Bo","Yang, Fan","Cao, Sheng","Liu, Xu","Xiang, Yaozu","Zhao, Qinyan","Huang, He","Yang, Bo","Huang, Congxin","32391877"],"abstract":["AIMS: To investigate the characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019 (COVID-19). METHODS AND RESULTS: We enrolled 671 eligible hospitalized patients with severe COVID-19 from 1 January to 23 February 2020, with a median age of 63 years. Clinical, laboratory, and treatment data were collected and compared between patients who died and survivors. Risk factors of death and myocardial injury were analysed using multivariable regression models. A total of 62 patients (9.2%) died, who more often had myocardial injury (75.8% vs. 9.7%; P < 0.001) than survivors. The area under the receiver operating characteristic curve of initial cardiac troponin I (cTnI) for predicting in-hospital mortality was 0.92 [95% confidence interval (CI), 0.87-0.96; sensitivity, 0.86; specificity, 0.86; P < 0.001]. The single cut-off point and high level of cTnI predicted risk of in-hospital death, hazard ratio (HR) was 4.56 (95% CI, 1.28-16.28; P = 0.019) and 1.25 (95% CI, 1.07-1.46; P = 0.004), respectively. In multivariable logistic regression, senior age, comorbidities (e.g. hypertension, coronary heart disease, chronic renal failure, and chronic obstructive pulmonary disease), and high level of C-reactive protein were predictors of myocardial injury. CONCLUSION: The risk of in-hospital death among patients with severe COVID-19 can be predicted by markers of myocardial injury, and was significantly associated with senior age, inflammatory response, and cardiovascular comorbidities."],"journal":"Eur Heart J","authors":["Shi, Shaobo","Qin, Mu","Cai, Yuli","Liu, Tao","Shen, Bo","Yang, Fan","Cao, Sheng","Liu, Xu","Xiang, Yaozu","Zhao, Qinyan","Huang, He","Yang, Bo","Huang, Congxin"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32391877","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1093/eurheartj/ehaa408","keywords":["coronavirus disease 2019","mortality","myocardial injury","risk"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666528580191911936,"score":103.20161},{"pmid":32502509,"title":"The association between severe or death COVID-19 and autoimmune disease: a systematic review and meta-analysis.","text":["The association between severe or death COVID-19 and autoimmune disease: a systematic review and meta-analysis.","J Infect","Liu, Ming","Gao, Ya","Zhang, Yuejun","Shi, Shuzhen","Chen, Yamin","Tian, Jinhui","32502509"],"journal":"J Infect","authors":["Liu, Ming","Gao, Ya","Zhang, Yuejun","Shi, Shuzhen","Chen, Yamin","Tian, Jinhui"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32502509","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.jinf.2020.05.065","keywords":["covid-19","meta-analysis","mortality","severity","autoimmune disease"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1668804508820439040,"score":77.1033},{"pmid":32375560,"title":"SARS-CoV-2-Induced Immune Dysregulation and Myocardial Injury Risk in China: Insights from the ERS-COVID-19 Study.","text":["SARS-CoV-2-Induced Immune Dysregulation and Myocardial Injury Risk in China: Insights from the ERS-COVID-19 Study.","Circ Res","Li, Dongze","Chen, You","Jia, Yu","Tong, Le","Tong, Jiale","Wang, Wei","Liu, Yanmei","Wan, Zhi","Cao, Yu","Zeng, Rui","32375560"],"journal":"Circ Res","authors":["Li, Dongze","Chen, You","Jia, Yu","Tong, Le","Tong, Jiale","Wang, Wei","Liu, Yanmei","Wan, Zhi","Cao, Yu","Zeng, Rui"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32375560","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1161/CIRCRESAHA.120.317070","keywords":["covid-19","immune dysregulation","mortality","myocardial injury"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666597097297674240,"score":71.91474},{"pmid":32360126,"title":"Myocardial injury and COVID-19: Possible mechanisms.","text":["Myocardial injury and COVID-19: Possible mechanisms.","Coronavirus Disease 2019 (COVID-19) has quickly progressed to a global health emergency. Respiratory illness is the major cause of morbidity and mortality in these patients with the disease spectrum ranging from asymptomatic subclinical infection, to severe pneumonia progressing to acute respiratory distress syndrome. There is growing evidence describing pathophysiological resemblance of SARS-CoV-2 infection with other coronavirus infections such as Severe Acute Respiratory Syndrome coronavirus and Middle East Respiratory Syndrome coronavirus (MERS-CoV). Angiotensin Converting Enzyme-2 receptors play a pivotal role in the pathogenesis of the virus. Disruption of this receptor leads to cardiomyopathy, cardiac dysfunction, and heart failure. Patients with cardiovascular disease are more likely to be infected with SARS-CoV-2 and they are more likely to develop severe symptoms. Hypertension, arrhythmia, cardiomyopathy and coronary heart disease are amongst major cardiovascular disease comorbidities seen in severe cases of COVID-19. There is growing literature exploring cardiac involvement in SARS-CoV-2. Myocardial injury is one of the important pathogenic features of COVID-19. As a surrogate for myocardial injury, multiple studies have shown increased cardiac biomarkers mainly cardiac troponins I and T in the infected patients especially those with severe disease. Myocarditis is depicted as another cause of morbidity amongst COVID-19 patients. The exact mechanisms of how SARS-CoV-2 can cause myocardial injury are not clearly understood. The proposed mechanisms of myocardial injury are direct damage to the cardiomyocytes, systemic inflammation, myocardial interstitial fibrosis, interferon mediated immune response, exaggerated cytokine response by Type 1 and 2 helper T cells, in addition to coronary plaque destabilization, and hypoxia.","Life Sci","Babapoor-Farrokhran, Savalan","Gill, Deanna","Walker, Jackson","Rasekhi, Roozbeh Tarighati","Bozorgnia, Behnam","Amanullah, Aman","32360126"],"abstract":["Coronavirus Disease 2019 (COVID-19) has quickly progressed to a global health emergency. Respiratory illness is the major cause of morbidity and mortality in these patients with the disease spectrum ranging from asymptomatic subclinical infection, to severe pneumonia progressing to acute respiratory distress syndrome. There is growing evidence describing pathophysiological resemblance of SARS-CoV-2 infection with other coronavirus infections such as Severe Acute Respiratory Syndrome coronavirus and Middle East Respiratory Syndrome coronavirus (MERS-CoV). Angiotensin Converting Enzyme-2 receptors play a pivotal role in the pathogenesis of the virus. Disruption of this receptor leads to cardiomyopathy, cardiac dysfunction, and heart failure. Patients with cardiovascular disease are more likely to be infected with SARS-CoV-2 and they are more likely to develop severe symptoms. Hypertension, arrhythmia, cardiomyopathy and coronary heart disease are amongst major cardiovascular disease comorbidities seen in severe cases of COVID-19. There is growing literature exploring cardiac involvement in SARS-CoV-2. Myocardial injury is one of the important pathogenic features of COVID-19. As a surrogate for myocardial injury, multiple studies have shown increased cardiac biomarkers mainly cardiac troponins I and T in the infected patients especially those with severe disease. Myocarditis is depicted as another cause of morbidity amongst COVID-19 patients. The exact mechanisms of how SARS-CoV-2 can cause myocardial injury are not clearly understood. The proposed mechanisms of myocardial injury are direct damage to the cardiomyocytes, systemic inflammation, myocardial interstitial fibrosis, interferon mediated immune response, exaggerated cytokine response by Type 1 and 2 helper T cells, in addition to coronary plaque destabilization, and hypoxia."],"journal":"Life Sci","authors":["Babapoor-Farrokhran, Savalan","Gill, Deanna","Walker, Jackson","Rasekhi, Roozbeh Tarighati","Bozorgnia, Behnam","Amanullah, Aman"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32360126","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.lfs.2020.117723","keywords":["cardiovascular disease","coronavirus disease 2019","mechanisms of myocardial injury","myocardial injury","myocarditis","severe acute respiratory syndrome coronavirus-2"],"topics":["Mechanism"],"weight":1,"_version_":1666138495507234818,"score":70.543045}]}